SCHEMBL21591777

SCHEMBL21591777

NCc1ccc(Oc2ccnc3[nH]cc(-c4cccc(OCc5ccccc5)c4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.47
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
SGK1 O00141 1/20 0.43
DYRK1A Q13627 1/20 0.43
DYRK2 Q92630 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
MAOB P27338 1/20 0.43
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
PRKDC P78527 1/20 0.40
CYP11B1 P15538 2/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
PTK6 Q13882 1/20 0.39
LRRK2 Q5S007 1/20 0.39
SYK P43405 1/20 0.39
LTA4H P09960 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29836484 1.00 IGF1R (0.47) IGF1RJAK2JAK3SGK1DYRK1A
SCHEMBL21593103 0.90 MET (0.42) IGF1RJAK2JAK3SGK1DYRK1A
SCHEMBL29836462 0.90 MET (0.42) IGF1RJAK2JAK3SGK1DYRK1A
SCHEMBL29836588 0.83 DYRK1A (0.44) IGF1RJAK2JAK3SGK1DYRK1A
SCHEMBL21591759 0.83 DYRK1A (0.44) IGF1RJAK2JAK3SGK1DYRK1A
SCHEMBL15032652 0.77 JAK3 (0.63) IGF1RJAK2JAK3DYRK1ADYRK2
SCHEMBL4352664 0.77 PIK3CG (0.61) IGF1RJAK2JAK3DYRK1ADYRK2
SCHEMBL30576680 0.74 CDC7 (0.61) JAK2JAK3DYRK1APIM1PTK6
SCHEMBL1668600 0.74 CDC7 (0.61) JAK2JAK3DYRK1APIM1PTK6
SCHEMBL14115599 0.74 PIK3CG (0.52) IGF1RJAK2JAK3DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP claimed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US claimed
EP-3807273-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2021-04-21 EP claimed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO claimed
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA IGF1R 2725/4885JAK2 946/4885JAK3 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.